Lab Markers May Guide Lupus Biologic Use

Analysis of 31 trials links serologic activity and disease severity to improved response.

1

Routine serologic markers and baseline disease activity may help identify lupus patients likely to benefit from biologic therapies.
2

Biologic therapies showed higher clinical response rates compared to standard treatment in a meta-analysis of over 17,000 patients.
3

Patients with serologically active disease, particularly those with anti-dsDNA antibodies and low complement levels, had better responses.
4

Higher baseline disease activity, indicated by a SLE Disease Activity Index score of 10 or greater, correlated with improved response to biologics.
5

Biologic therapies targeting B-cell activating factor demonstrated consistent efficacy, while other mechanisms showed variable results.

1